PUBLIC COMPANY
saveCHENGDU
USupdated 6mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Evommune signs $1B deal with China’s Hinova to enter same molecular glue niche as NovartisEvommune has paid $30 million to China’s Hinova Pharmaceuticals to get stuck into a niche of preclinical molecular glue degrader development that’s also being pursued by Novartis.fiercebiotech · 1d ago
- 6 potential blockbusters that could pave China’s path to 2030 ambitionsIn its latest five-year plan, China has set its sights on developing five drugs that could each rake in more than $1 billion globally by 2030. Experts say it's well on its way, with two medications…biospace · 2d ago
- iRegene Therapeutics’s NouvSight001 Cleared for Clinical Trials in the U.S. and China for Retinitis PigmentosaFollowing its Parkinson’s disease program, iRegene advances another off-the-shelf cell therapy into clinical development in the U.S. and China.fiercebiotech · 1mo ago
comments(0)
5-min edit window · permanent after that